Q4 FY22 Earnings Presentation

Q3 FY22 Revenue by portfolio and geography Worldwide U.S. Table of Executive Portfolio Financial Guidance & Contents Summary Highlights Highlights Assumptions Non-U.S. Developed ESG Appendix Emerging Markets Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Revenue ($M)¹ As reported Y/Y% Organic Y/Y% Cardiovascular 2,745 1.4% 3.4% 1,297 2.0% 2.0% 935 -0.6% 4.1% 513 4.1% 5.9% Cardiac Rhythm & 1,402 2.3% 4.2% Hearth Failure Structural Heart & 740 1.4% 3.7% Aortic Coronary & Peripheral Vascular 603 -0.3% 1.3% Medical Surgical 2,290 -1.0% 1.2% 990 3.2% 3.2% 812 -6.5% -2.1% 488 0.4% 2.9% Surgical Innovations 1,519 6.7% 9.2% Respiratory, Gastrointestinal, & Renal 771 -13.4% -11.6% Neuroscience 2,144 0.8% 1.8% 1,397 -0.3% -0.3% 431 -2.9% 2.0% 316 12.9% 12.5% Cranial & Spinal 1,102 1.9% 3.1% Technologies Specialty Therapies 633 2.4% 3.1% Neuromodulation 409 -4.0% -2.8% Diabetes 584 -7.3% -5.4% 255 -16.9% -16.9% 261 -2.6% 1.1% 68 23.6% 25.5% Total Medtronic 7,763 -0.2% 1.6% 3,939 0.0% 0.0% 2,438 -3.3% 1.2% 1,385 5.4% 7.1% ¹Data has been intentionally rounded to the nearest million and, therefore, may not sum 31 Q3 FY22 earnings presentation | February 22, 2022 Medtronic

View entire presentation